SpringWorks Therapeutics (NASDAQ:SWTX) Receives Outperform Rating from Wedbush

Wedbush reiterated their outperform rating on shares of SpringWorks Therapeutics (NASDAQ:SWTX) in a research note issued to investors on Thursday morning,RTT News reports. They currently have a $81.00 price target on the stock. Wedbush also issued estimates for SpringWorks Therapeutics’ Q2 2025 earnings at ($0.68) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($2.43) EPS, FY2026 earnings at $0.23 EPS, FY2027 earnings at $3.55 EPS and FY2028 earnings at $8.09 EPS.

A number of other research analysts also recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $74.00 target price on shares of SpringWorks Therapeutics in a research report on Wednesday, February 12th. Evercore ISI increased their price objective on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 12th. Finally, Guggenheim lowered their target price on SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $71.50.

SpringWorks Therapeutics Stock Performance

Shares of SpringWorks Therapeutics stock opened at $59.93 on Thursday. The stock’s 50-day moving average is $40.70 and its 200-day moving average is $37.47. SpringWorks Therapeutics has a one year low of $28.21 and a one year high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its quarterly earnings results on Thursday, February 20th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.38). SpringWorks Therapeutics had a negative return on equity of 48.21% and a negative net margin of 203.09%. Equities research analysts expect that SpringWorks Therapeutics will post -3.17 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Saqib Islam sold 48,000 shares of SpringWorks Therapeutics stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $53.30, for a total transaction of $2,558,400.00. Following the sale, the chief executive officer now directly owns 1,002,502 shares of the company’s stock, valued at approximately $53,433,356.60. The trade was a 4.57 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Daniel Pichl sold 29,750 shares of SpringWorks Therapeutics stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $54.36, for a total transaction of $1,617,210.00. Following the sale, the insider now directly owns 50,762 shares in the company, valued at $2,759,422.32. This trade represents a 36.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 313,822 shares of company stock worth $16,802,876 in the last 90 days. Company insiders own 7.61% of the company’s stock.

Institutional Trading of SpringWorks Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of SWTX. FMR LLC grew its position in SpringWorks Therapeutics by 0.3% during the 3rd quarter. FMR LLC now owns 11,140,946 shares of the company’s stock worth $356,956,000 after acquiring an additional 28,555 shares during the last quarter. Vanguard Group Inc. grew its position in SpringWorks Therapeutics by 6.6% during the 4th quarter. Vanguard Group Inc. now owns 7,158,871 shares of the company’s stock worth $258,650,000 after acquiring an additional 445,593 shares during the last quarter. Boxer Capital Management LLC bought a new stake in shares of SpringWorks Therapeutics during the fourth quarter worth about $123,620,000. Maverick Capital Ltd. grew its holdings in shares of SpringWorks Therapeutics by 6.8% during the third quarter. Maverick Capital Ltd. now owns 2,778,348 shares of the company’s stock worth $89,018,000 after purchasing an additional 177,824 shares during the last quarter. Finally, Pictet Asset Management Holding SA grew its holdings in shares of SpringWorks Therapeutics by 24.2% during the fourth quarter. Pictet Asset Management Holding SA now owns 2,391,412 shares of the company’s stock worth $86,402,000 after purchasing an additional 465,494 shares during the last quarter.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.